Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus PCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus PCE.
E.E.S. 200 vs PCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
PCE (erythromycin) binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptides.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
Erythromycin ethylsuccinate (PCE) typical adult dose: 400 mg orally every 6 hours or 800 mg orally every 12 hours. Maximum 4 g/day.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to 7-10 hours in renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily renal (about 70-80% as unchanged drug and metabolites via glomerular filtration and tubular secretion); minor biliary/fecal elimination (10-15%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic